Skip to main content
Moleculin Biotech, Inc. logo

Moleculin Biotech, Inc. - Investor Relations & Filings

Listed IPO Jun 2016
Ticker · MBRX ISIN · US60855D2009 LEI · 549300IB1TLJZCHEO353 US Manufacturing
Open in API
Filings indexed 786 across all filing types
Latest filing 2025-12-23 Capital/Financing Update
Country US United States of America
Listing US MBRX · 6 venues

About Moleculin Biotech, Inc.

https://moleculin.com/

Moleculin Biotech, Inc. is a late-stage clinical pharmaceutical company focused on developing a portfolio of therapeutic candidates for highly resistant cancers and viruses. The company's lead drug candidate is Annamycin, a next-generation liposomal anthracycline designed to be non-cardiotoxic and to circumvent multidrug resistance. Annamycin is being advanced in a pivotal Phase 3 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company's development pipeline also includes other drug candidates targeting hard-to-treat tumors.

Recent filings

Filing Released Lang Actions
FORM 424B5
Capital/Financing Update Classification · 95% confidence The document is a 'Prospectus Supplement' filed pursuant to Rule 424(b)(5) and relates to an At The Market Offering Agreement (ATM Agreement) for common stock. It updates the maximum aggregate gross sales price of common stock that may be offered and sold under the ATM Agreement. The document is focused on financing activities, specifically the increase in the size of the ATM offering and details about shares sold and public float. It is not a full financial report, earnings release, or management discussion, but rather an update on capital raising activities. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is 4006 characters, which is consistent with a detailed supplement rather than a brief announcement or a full report.
2025-12-23 English
FORM PRER14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A Proxy Statement filed pursuant to Section 14(a) of the Securities Exchange Act of 1934. It is a solicitation of proxies for a Special Meeting of Stockholders, detailing proposals to be voted on, voting procedures, and recommendations from the Board of Directors. The content includes detailed information about the meeting, proposals, voting instructions, and other related information typically found in proxy statements. It is not an announcement of voting results, nor is it a report of financial results or management discussion. The document is not a report publication announcement or a certification. Therefore, the document fits the category of Proxy Solicitation & Information Statement (PSI). The document length is substantial (15,000 characters), indicating it is the full proxy statement, not just a brief announcement or notice.
2025-12-22 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content includes details about a material definitive agreement (warrant amendments), updates on compliance with Nasdaq listing rules, and steps taken to regain compliance including capital raising activities. It also references a delisting determination and appeal process. The document does not contain full financial statements or comprehensive financial analysis typical of Annual Reports (10-K) or Interim Reports (IR). It is not a transcript, proxy, or remuneration report. The focus is on material agreements and regulatory compliance events, which are typical for a Current Report (8-K). Given the nature of the content and the SEC form type, the best fitting category is Regulatory Filings (RNS). The document length (7540 characters) and detailed event description support this classification with high confidence.
2025-12-22 English
FORM PRE 14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A Proxy Statement filed with the SEC, as indicated by the header and the text. It is a solicitation of proxies for a Special Meeting of Stockholders, detailing proposals to be voted on, voting procedures, and other related information. The document includes a Notice of Special Meeting and a Proxy Statement, which are materials sent to shareholders to provide information and request votes for meetings. It is not an announcement of voting results, nor is it a full annual or quarterly report, earnings release, or other financial report. The document is lengthy (15,000 characters) and contains detailed proxy solicitation information, which fits the definition of Proxy Solicitation & Information Statement (PSI).
2025-12-19 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce specific events or disclosures outside of regular periodic filings. The text mentions a press release about positive clinical trial results attached as Exhibit 99.1. There are no financial statements or detailed financial data included in the text. The document is relatively short (3874 characters) and primarily serves to announce the press release and provide regulatory disclosure. This fits the profile of a Regulatory Filing (RNS) rather than a full report like an Annual Report (10-K) or Interim Report (IR).
2025-12-17 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, which is used for reporting unscheduled material events or corporate changes. The content specifically discusses a Nasdaq deficiency letter regarding the company's stock price falling below the minimum bid price requirement and a subsequent letter confirming the company regained compliance. This is an update on regulatory compliance related to listing status, not a full financial report, earnings release, or management discussion. The document is relatively short (3519 characters) and serves as a regulatory announcement rather than a detailed report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-12-16 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.